Literature DB >> 6432920

Functional analysis of tyrosinase isozymes of cultured malignant melanoma cells during the recovery period following interrupted melanogenesis induced by glycosylation inhibitors.

G Imokawa, Y Mishima.   

Abstract

Multiple forms of tyrosinase, T1, T2, T3, have been shown to differ with respect to carbohydrate moieties of these isozymes. We demonstrated that, in cultured B-16 melanoma cells, melanization can be completely interrupted by glycosylation inhibitors, such as glucosamine and tunicamycin, and that these inhibitors cause a selective loss of membrane-bound T3. It is further found that inhibition of melanization induced by glucosamine occurs even in the presence of protease inhibitors, such as phenylmethylsulfonyl fluoride and leupeptin, and that melanization inhibition is reversible upon removal of the inhibitor. In this report we have also examined the process of development and recovery of the tyrosinase isozymes in cells in which the interruption of melanogenesis has been released by the removal of these glycosylation inhibitors. The recovery process, which occurs during the period after interrupted melanogenesis and is a process of remelanization, has been biochemically followed. Tyrosinases obtained from the deoxycholate-solubilized large-granule fraction of these melanoma cells have been analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Immediately after removal (0 h recovery) of the glycosylation inhibitor, loss of melanization and T3 is accompanied by T1 heterogeneity which is visualized as two electrophoretically distinct species, T1' and T1''. At this time, T1' and T1'' do not have a concanavalin A affinitive carbohydrate moiety but do possess in vitro dopa reactivity. When recovery of melanization begins visibly 24 h later, T3 is re-formed with disappearance of T1 heterogeneity. By 48 h, the previous normal level of melanization is almost attained. These results suggest that maturation of tyrosinase may occur via T1' and T1'' as precursors of T3, or possibly T1 through the addition of N-glycosydically linked oligosaccharide moieties which can be interrupted by glucosamine and tunicamycin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432920     DOI: 10.1111/1523-1747.ep12263562

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Oculocutaneous albinism type 1: link between mutations, tyrosinase conformational stability, and enzymatic activity.

Authors:  Monika B Dolinska; Nicole J Kus; S Katie Farney; Paul T Wingfield; Brian P Brooks; Yuri V Sergeev
Journal:  Pigment Cell Melanoma Res       Date:  2017-01       Impact factor: 4.693

2.  Arenarol isolated from a marine sponge abrogates endothelin-1-stimulated melanogenesis by interrupting MEK phosphorylation in normal human melanocytes.

Authors:  Bong-Keun Choi; Byung-Yoon Cha; Takeshi Fujiwara; Akihiko Kanamoto; Je-Tae Woo; Makoto Ojika; Genji Imokawa
Journal:  Cytotechnology       Date:  2013-05-01       Impact factor: 2.058

3.  Purification of Recombinant Human Tyrosinase from Insect Larvae Infected with the Baculovirus Vector.

Authors:  Monika B Dolinska; Paul T Wingfield; Yuri V Sergeev
Journal:  Curr Protoc Protein Sci       Date:  2017-08-01

4.  Niosome as a drug carrier for topical delivery of N-acetyl glucosamine.

Authors:  M A Shatalebi; S A Mostafavi; A Moghaddas
Journal:  Res Pharm Sci       Date:  2010-07

5.  Human Tyrosinase: Temperature-Dependent Kinetics of Oxidase Activity.

Authors:  Kenneth L Young; Claudia Kassouf; Monika B Dolinska; David Eric Anderson; Yuri V Sergeev
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

Review 6.  Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration.

Authors:  Jody P Ebanks; R Randall Wickett; Raymond E Boissy
Journal:  Int J Mol Sci       Date:  2009-09-15       Impact factor: 6.208

7.  The consequences of deglycosylation of recombinant intra-melanosomal domain of human tyrosinase.

Authors:  Monika B Dolinska; Yuri V Sergeev
Journal:  Biol Chem       Date:  2017-12-20       Impact factor: 4.700

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.